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The atypical antipsychotic clozapine is widely used for treatment-resistant schizophrenic 
patients. Clozapine and its major active metabolite, N-desmethylclozapine (NDMC), 
have complex pharmacological properties, and interact with various neurotransmitter 
receptors. There are several biochemical studies reporting that NDMC exhibits a partial 
agonist profile at the human recombinant M1 muscarinic receptors. However, direct 
electrophysiological evidence showing the ability of NDMC to activate native M1 
receptors in intact neurons is poor. Using rat hippocampal neurons, we previously 
demonstrated that activation of muscarinic receptors by a muscarinic agonist, 
oxotremorine M (oxo-M), induces a decrease in outward K+ current at -40 mV. In the 
present study, using this muscarinic current response we assessed agonist and antagonist 
activities of clozapine and NDMC at native muscarinic receptors in intact hippocampal 
excitatory and inhibitory neurons. Suppression of the oxo-M-induced current response by 
the M1 antagonist pirenzepine was evident only in excitatory neurons, while the M3 
antagonist darifenacin was effective in both types of neurons. Muscarinic agonist activity 
of NDMC was higher than that of clozapine, higher in excitatory neurons than in 
inhibitory neurons, sensitive to pirenzepine, and partially masked when co-applied with 
clozapine. Muscarinic antagonist activity of clozapine as well as NDMC was not different 
between excitatory and inhibitory neurons, but clozapine was more effective than NDMC. 
These results demonstrate that NDMC has the ability to activate native M1 receptors 
expressed in hippocampal excitatory neurons, but its agonist activity might be limited in 
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1. Introduction 
Clozapine is a unique antipsychotic drug, and currently classified as first-line treatment in 
treatment-resistant schizophrenia (Buchanan et al., 2010; Dold and Leucht, 2014; Hasan 
et al., 2012; Leucht et al., 2003). Clozapine improves positive and negative symptoms, 
while inducing minimal extrapyramidal side effects (Divac et al., 2014). Clozapine and 
its predominant active metabolite, N-desmethylclozapine  (NDMC), have complex 
pharmacological profiles, and interact with a wide range of neurotransmitter receptors 
including dopamine, serotonin, norepinephrine, histamine and acetylcholine receptors 
(Correll, 2010; Lameh et al., 2007; Mendoza and Lindenmayer, 2009; Weiner et al., 2004). 
Although the antipsychotic efficacy of clozapine is thought to be based primarily on its 
interaction with dopamine and serotonin receptors, the interactions of clozapine and 
NDMC with muscarinic receptors could also contribute to the therapeutic efficacy 
(Lameh et al., 2007; Maehara et al., 2011a; Maehara et al., 2011b). Among the muscarinic 
receptor subtypes (M1-M5), much attention has been given to M1 receptors, because it is 
implicated in learning and memory processes (Anagnostaras et al., 2003; Shirey et al., 
2009). Biochemical studies demonstrated that NDMC exhibits a partial agonist profile at 
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human recombinant M1 receptors (Davies et al., 2005), which seems to be unique and not 
shared by any other antipsychotics. However, direct electrophysiological evidence 
showing the ability of NDMC to activate native M1 receptors in intact neurons is poor.  
 We previously reported that in rat cultured hippocampal neurons the activation 
of muscarinic receptors by applying the muscarinic agonist oxotremorine M (oxo-M) 
decreased the steady-state outward current at -40 mV, which was attributed to inhibition 
of K+ channels sensitive to the M-current blocker XE991 (Sugawara et al., 2013). This 
muscarinic current response was inhibited by the phospholipase C (PLC) inhibitor 
U73122, but not its inactive analogue U73343, indicating the involvement of 
PLC-coupled types of muscarinic receptors including M1 and M3 subtypes (Sugawara et 
al., 2013). In the present study, using this muscarinic current response we assessed 
muscarinic agonist and antagonist activities of clozapine and NDMC in intact 
hippocampal excitatory and inhibitory neurons. 
 
2. Results 
2.1 Effects of the muscarinic agonist oxo-M 
In cultured hippocampal neurons, we previously demonstrated that the activation of 
muscarinic receptors by the muscarinic agonist oxo-M decreases the steady-state outward 
K+ current at -40 mV. To examine whether there are cell-type differences in this coupling 
of muscarinic receptors to K+ channels, effects of oxo-M application on the outward 
current were compared between excitatory and inhibitory neurons. The steady-state 
outward current before the oxo-M application varied from neuron to neuron. On average, 
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it was larger in inhibitory neurons (209.8 ± 10.5 pA, n = 123) than in excitatory neurons 
(132.9 ± 5.8 pA, n = 84). Bath application of 3 μM oxo-M markedly decreased the 
outward current in both types of neurons (Fig. 1A). The percentage reduction of the 
outward current by oxo-M was slightly larger in excitatory neurons than in inhibitory 
neurons, but the difference was not significant (Fig. 1B, P = 0.068, unpaired t test). These 
results indicate that both types of neurons express muscarinic receptors that negatively 
regulate the K+ channels active at -40 mV. 
 
2.2 Effects of subtype-selective muscarinic antagonists 
Using relatively selective antagonists for M1 (pirenzepine) and M3 (darifenacin) subtypes 
of muscarinic receptors, contributions of M1 and M3 subtypes to the oxo-M-induced 
current responses were examined. The M1 antagonist pirenzepine (0.1 μM) partially 
suppressed the current response in excitatory neurons (Fig. 2A, 2C), but not in inhibitory 
neurons (Fig. 2B, 2C). The difference between excitatory and inhibitory neurons was 
significant (P < 0.05, unpaired t test). On the other hand, the M3 antagonist darifenacin (1 
μM) suppressed the current response strongly in both excitatory and inhibitory neurons 
(Fig. 3). The antagonistic effect of darifenacin was larger in inhibitory neurons than in 
excitatory neurons (Fig. 3C), but the difference was not significant (P = 0.071, unpaired t 
test). These results indicate that relative contributions of M1 and M3 receptors to the 
channel modulation are different between excitatory and inhibitory neurons, and that M1 
receptors contribute to the channel modulation selectively in excitatory neurons. 
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2.3 Agonist activities of clozapine and NDMC at muscarinic receptors  
To assess the agonist activity at muscarinic receptors, effects of clozapine (Fig. 4A) and 
NDMC (Fig. 4B) on the holding current at -40 mV were examined in excitatory (left) and 
inhibitory neurons (right) separately. To mimic intracerebral conditions of 
clozapine-treated patients, we also examined effects of co-application of NDMC and 
clozapine (Fig. 4C). If they function as muscarinic agonists, they are expected to decrease 
the outward current. A two-way ANOVA (cell type × drug) revealed a significant 
interaction effect of cell type and drug (F = 6.68, P < 0.01). Bath-applied clozapine (3 
μM) induced no or only a small effect in both types of neurons (Fig. 4A, 4D). Application 
of 3 μM NDMC greatly decreased the outward current in excitatory neurons, but not in 
inhibitory neurons (Fig. 4B). The NMDA-induced current response was significantly 
larger in excitatory neurons than in inhibitory ones (Fig. 4D, P < 0.01). In excitatory 
neurons, NDMC alone was more effective than either clozapine alone (P < 0.05) or the 
combination of clozapine and NDMC (P < 0.05) (Fig. 4D). The effect of NDMC in 
excitatory neurons was significantly suppressed by 0.1 μM pirenzepine (P < 0.05) and 1 
μM atropine (P < 0.001) (Fig. 5). These results indicate that NDMC has an agonist 
activity at native M1 receptors of hippocampal excitatory neurons. 
 
2.4 Antagonist activities of clozapine and NDMC on muscarinic receptors  
To assess the antagonist activity at muscarinic receptors, effects of clozapine and NDMC, 
alone or in combination, on the holding current at -40 mV were examined after 
application of oxo-M. If the drug has an antagonist activity, the suppression of the 
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outward current by oxo-M is expected to be reversed upon its application. When 
clozapine or NDMC, or both, was applied in the presence of oxo-M, the outward current 
was markedly reversed in both excitatory and inhibitory neurons (Fig. 6). A two-way 
ANOVA (cell type × drug) showed no significant interaction effect of cell type and drug 
(F = 0.721, P = 0.491). There was a significant main effect of drug (F = 5.02, P < 0.05), 
but not cell type (F = 1.04, P = 0.314). The antagonist activity of clozapine was 
significantly larger than that of NDMC (Fig. 6D, P < 0.01).  
 
3. Discussions 
The present study is the first attempt to examine agonist and antagonist activities of 
clozapine and NDMC at PLC-coupled types of muscarinic receptors including M1 and M3 
subtypes by monitoring muscarinic current responses in intact hippocampal excitatory 
and inhibitory neurons separately. Our data confirmed that clozapine acts primarily as an 
antagonist, whereas NDMC acts as a mixed agonist-antagonist. The muscarinic agonist 
activity of NDMC was found to be higher in excitatory neurons than in inhibitory neurons, 
and sensitive to pirenzepine. We also confirmed cell-type differences in the effects of 
pirenzepine and darifenacin on oxo-M-induced current responses, indicating that the 
contribution of M1 receptors to the muscarinic responses is evident only in excitatory 
neurons. These results strongly suggest that the agonist activity of NDMC depends on the 
M1, rather than M3, subtype, in agreement with some biochemical studies reporting that 
NDMC exhibits a partial agonist profile at M1 receptors (Davies et al., 2005; Gregory et 
al., 2007; Weiner et al., 2004). 
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 Our electrophysiological data suggested that M3 receptors mediate the 
muscarinic suppression of potassium channels in both excitatory and inhibitory 
hippocampal neurons, whereas M1 receptors contribute to the muscarinic channel 
modulation only in the excitatory neurons. These data are consistent with previous 
anatomical and electrophysiological studies on hippocampal M1 and M3 receptors. 
Yamasaki et al. examined cellular and subcellular distribution of M1 receptors in the 
cerebral cortex and hippocampus, and demonstrated that M1 receptors are expressed 
preferentially in glutamatergic pyramidal neurons, and scarce or undetectable in various 
GABAergic interneuron subtypes (Yamasaki et al., 2010). Instead of M1 receptors, M3 
receptors were detectable in interneurons (Yamasaki et al., 2010).  Using mice genetically 
lacking specific muscarinic receptor subtypes, receptor subtypes responsible for 
cholinergic modulation of ion channels have been identified in hippocampal pyramidal 
neurons (Dasari and Gulledge, 2011; Rouse et al., 2000). Rouse et al. reported that the 
muscarinic inhibition of K+ channels remained intact in the pyramidal neurons prepared 
from M1-knockout mice (Rouse et al., 2000). Dasari and Gulledge reported that 
carbachol-induced depolarization was reduced in neurons from either M1-knockout or 
M3-knockout mice, and was eliminated in M1/M3 double-knockout mice (Dasari and 
Gulledge, 2011). These results are compatible with the idea that both M1 and M3 receptors 
are functional in pyramidal neurons.   
There has been some dispute as to whether NDMC has M1 agonist activity at 
native rat M1 receptors. Using rat cerebral cortical and hippocampal membranes, M1 
muscarinic receptor-mediated Gq activation was pharmacologically characterized. The 
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study failed to detect the M1 agonist activity of NDMC (Odagaki et al., 2013). By contrast, 
an electrophysiological study clearly demonstrated that NDMC has an M1 agonist activity 
in intact hippocampal neurons (Sur et al., 2003). Using CA1 pyramidal neurons, Sur et al. 
demonstrated that bath application of NDMC potentiated the current response evoked by 
fast application (0.5-1.5 s) of N-methyl-D-aspartate (NMDA). Considering these results 
together with previous reports of M1-mediated potentiation of NMDA receptors together, 
the authors concluded that NDMC has an M1 agonist activity, in agreement with the 
present study. In the study by Sur et al, however, electrophysiological experiments were 
carried out to examine only an M1 agonist action of NDMC, using only pyramidal cells. 
Therefore, comparisons between pyramidal cells and interneurons, between NDMC and 
clozapine, and between agonist and antagonist actions were not performed. In the present 
study, we used both excitatory and inhibitory neurons, and examined both agonist and 
antagonist activities of NDMC and clozapine at muscarinic receptors. Our experimental 
data highlight that NDMC, but not clozapine, has the potential to depolarize excitatory 
neurons selectively by inhibiting potassium channels.  
 We observed that the M1 agonist action of NDMC was largely masked when the 
same concentration of clozapine was co-applied. In clozapine-treated patients, the median 
plasma clozapine/NDMC concentration ratio has been reported to be 1.25 and 2.08 at 
plasma clozapine concentrations < 0.35 mg/L and > 1.0 mg/L, respectively (Couchman et 
al., 2010). Experimental studies in laboratory animals demonstrated that the 
clozapine/NDMC ratio in the brain is higher than that in the plasma (Gershkovich et al., 
2010; Weigmann et al., 1999). Accordingly, the activation of M1 receptors by NDMC in 
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the brain seems to be limited in most clozapine-treated patients, because of the presence 
of excessive clozapine. In some patients with a low clozapine/NDMC ratio, however, it is 
still possible that M1 receptors are partially activated by NDMC. In line with this 
possibility, a recent study in clozapine-treated patients demonstrated that the 
clozapine/NDMC ratio, but not individual clozapine and NDMC concentrations, was 
significantly and negatively associated with working memory performance after 
controlling for age, gender, education, and symptom severity (Rajji et al., 2015).   
 
4. Conclusions 
In the present study, we assessed agonist and antagonist activities of clozapine and its 
major active metabolite, NDMC, at native muscarinic receptors in rat intact hippocampal 
excitatory and inhibitory neurons, by monitoring muscarinic current responses. Our data 
clearly demonstrated that clozapine acts primarily as an antagonist, whereas NDMC acts 
as a mixed agonist-antagonist. The agonist activity of NDMC, which was explained by its 
action on the M1, rather than M3, subtype, was largely masked when the same 
concentration of clozapine was co-applied. These results suggest that the 
clozapine/NDMC concentration ratio in clozapine-treated patients might determine the 
degree of M1 receptor activation by NDMC. 
 
5. Experimental Procedure 
5.1 Preparation of neurons 
All experiments were performed in accordance with the guidelines set by the animal 
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welfare committee of Kanazawa University. Hippocampal neurons were prepared from 
newborn Sprague-Dawley rats, as described previously (Ohno-Shosaku et al., 2001). 
Briefly, following isoflurane anesthesia, rats were decapitated and cells were 
mechanically dissociated from the hippocampi and plated onto culture dishes (35 mm) 
pretreated with poly L-ornithine (0.01 %). The cultures were kept at 36 C in 5 % CO2 for 
13-19 days before use. 
 
5.2 Electrophysiology  
All experiments were performed at room temperature. Neurons were whole-cell voltage 
clamped using patch pipettes (3 –5 M) filled with an internal solution containing (in 
mM) 100 K-gluconate, 15 KCl, 10 HEPES, 10 EGTA, 6 MgCl2, 4.65 CaCl2, 40 KOH, 5 
Na2ATP and 0.2 Na2GTP (pCa 7, pH 7.3 adjusted with KOH). The whole-cell current was 
measured with a patch-clamp amplifier (EPC9/3, HEKA Electronics, Germany). A 
standard external solution contained (in mM) 140 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 
HEPES and 10 glucose (pH 7.3 adjusted with NaOH). 
 The hippocampus contains excitatory (glutamatergic) and inhibitory 
(GABAergic) neurons. The cell type was identified electrophysiologically in double 
whole-cell recordings, where two neurons were whole-cell voltage clamped at -80 mV. 
One neuron was stimulated by applying positive voltage pulses (to 0 mV, 2 ms), and the 
evoked excitatory or inhibitory postsynaptic currents (EPSCs or IPSCs) were recorded 
from the other neuron. IPSCs and EPSCs are easily distinguished by their decay time 
constants, reversal potentials and sensitivities to GABAA and AMPA receptor antagonists 
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(Ohno-Shosaku et al., 2011). When the postsynaptic currents were EPSCs or IPSCs, the 
presynaptic neuron was identified as inhibitory or excitatory, respectively. 
 The steady-state outward current was measured at the holding potential of -40 
mV. To suppress the generation of action potentials and spontaneous synaptic currents, 
0.1 μM tetrodotoxin (TTX) was added to the standard external solution. The holding 
current was recorded for 100 ms (sampling rate, 1 kHz) once every second, except for the 
experiments shown in Fig. 2 and 3, where the current was recorded every 200 ms. In 
figures, the averaged current values of each sweep are plotted as a function of time. The 
recording chamber was perfused with an external solution with or without drugs at a flow 
rate of 1-3 ml/min. 
 To assess agonist and antagonist activities at muscarinic receptors, the 
steady-state outward current at -40 mV was monitored. For agonist activity, the amplitude 
of the outward current before agonist application was taken as 100 % and the percentage 
reduction of the current was calculated. For antagonist activity, the amplitude of the 
current reduction induced by application of the muscarinic agonist oxo-M was taken as 
100 % and the percentage recovery of the current around 60 s after the application of the 
drug with antagonist activity was calculated.  
In some experiments (Fig. 2 and 3), the external solution containing oxo-M was 
locally applied for 5 s through a capillary tube (250 μm inner diameter) using a perfusion 
valve controller (VC-6M, Warner Instrument, CT). The applied agonist was rapidly 
washed out by continuous bath perfusion. When neurons were exposed to the antagonist 
(pirenzepine or darifenacin), it was added to both the bath solution and the local 
 14
application solution containing oxo-M. To calculate the antagonistic effect of these drugs, 
oxo-M was applied three times at intervals longer than 1 min in each neuron. In 
experiments with pirenzepine, the amplitude of oxo-M-induced current response was 
measured before (R1) and during the treatment with the drug (R2), and after its washout 
(R3). The antagonistic effect (E) was calculated by the following equation: E=1−2×
R2/(R1+R3). Data were discarded when R3 is less than 50% of R1. In experiments with 
darifenacin, the amplitude of oxo-M-induced current response was measured twice 
before the treatment (R1 and R2) and once during the treatment with the drug (R3). The 
antagonistic effect (E) was calculated by the following equation: E=1−R3/R2. Data were 
discarded when R2 is less than 70% of R1.  
 In all experiments, recordings were discarded when series resistance was > 20 
M at the beginning or > 25 M at the end of experiments, when the holding current at 
-40 mV was < 40 pA at the beginning of experiments or < 0 pA during oxo-M application, 
and when the amplitude of current response to oxo-M application was < 30 pA. 
 
5.3 Statistics 
All data are expressed as mean  S.E.M., with numbers of neurons given in parentheses. 
Statistical significance was evaluated by Student's unpaired t test and two-way ANOVA 
for 2 factors followed by post hoc unpaired t test with the use of the Bonferroni method. 
The differences with P < 0.05 were taken as significant. Single, double, and triple 




Oxo-M, pirenzepine, clozapine and NDMC were purchased from Tocris Cookson (UK), 
TTX and atropine were from Nacalai (Japan), and darifenacin was from Santa Cruz 
(USA). Darifenacin, clozapine and NDMC were dissolved in DMSO as stock solutions.  
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A comparison of current responses to the muscarinic agonist oxo-M between excitatory 
and inhibitory neurons. A: Representative current responses induced by bath application 
of 3 μM oxo-M in excitatory (left) and inhibitory (right) neurons. B: Mean data for the 




The antagonistic effect of pirenzepine on oxo-M-induced current responses in excitatory 
and inhibitory neurons. A, B: Representative examples of the experimental records from 
excitatory (A) and inhibitory (B) neurons. In each neuron, local application of oxo-M (3 
μM) was repeated in the absence and presence of pirenzepine (0.1 μM). C: Mean data for 
the suppression of the oxo-M-induced current response by pirenzepine in excitatory (left) 
and inhibitory neurons (right).  
 
Figure 3 
The antagonistic effect of darifenacin on oxo-M-induced current responses in excitatory 
and inhibitory neurons. A, B: Representative examples of the experimental records from 
excitatory (A) and inhibitory (B) neurons. Local application of oxo-M (3 μM) was 
repeated in the absence and presence of darifenacin (1 μM). C: Mean data for the 
suppression of the oxo-M-induced current response by darifenacin in excitatory (left) and 
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inhibitory neurons (right).  
  
Figure 4 
Abilities of clozapine and NDMC to decrease the outward current in excitatory and 
inhibitory neurons. A-C: Representative current responses induced by bath application of 
3 μM clozapine (A), 3 μM NDMC (B), and the mixture of 3 μM clozapine and 3 μM 
NDMC (C) in excitatory (left) and inhibitory (right) neurons. D: Mean data for the 
reduction of the outward current by clozapine (left), NDMC (middle) and the mixture 
(right) in excitatory (white bars) and inhibitory neurons (gray bars). 
 
Figure 5 
Antagonistic effects of pirenzepine and atropine on NDMC-induced current responses in 
excitatory neurons. A: Representative current responses induced by bath application of 3 
μM NDMC in the absence (left) or presence of 0.1 μM pirenzepine (middle) or 1 μM 
atropine (right). B: Mean data for the reduction of the outward current by NDMC with or 
without pirenzepine or atropine. 
 
Figure 6 
Abilities of clozapine and NDMC to recover the outward current from the oxo-M-induced 
suppression in excitatory and inhibitory neurons. A-C: Representative current responses 
induced by bath application of 3 μM clozapine (A), 3 μM NDMC (B), and the mixture of 
3 μM clozapine and 3 μM NDMC (C) in the presence of 3 μM oxo-M in excitatory (left) 
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and inhibitory (right) neurons. D: Mean data for the percentage recovery of the current 
from the oxo-M-induced suppression by clozapine (left), NDMC (middle) and the 
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